Respironics ( RESP - NASDAQ ) has just reported the last Q results . Part of RESPIRONICS biz is actually the second leg in the DUOPOLY of RMD/RESP in the APNEA sleep disorder market . Key drivers for the Company's domestic revenue performance include a year-over-year increase of 15 percent in domestic sleep therapy products. Let's hope RMD did the same . First call consensus expected increase for RMD is 12% in EPS growth .It is expected to report EPS USc 28 for the Q and USD 1.06 for the FY , Duff
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$40.64 |
Change
-0.040(0.10%) |
Mkt cap ! $23.56B | |||
| Open | High | Low | Value | Volume |
| $40.63 | $40.65 | $40.52 | $13.50M | 331.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 58 | $40.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $40.64 | 37 | 1 |
View Market Depth
| Last trade - 10.06am 16/09/2025 (20 minute delay) ? |
| RMD (ASX) Chart |